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A B S T R A C T
Background: Hypothyroidism is regarded as a risk factor
for coronary artery disease. Possible factors involved in
this association are hyperlipidaemia and hypertension,
both occurring with increased frequency in hypothyroid
patients. The aim of our study was to evaluate
signs/symptoms of cardiac ischaemia in untreated
hypothyroid patients without angina pectoris, since this
has never been performed before. 
Methods: 51 consecutive cardiac asymptomatic patients
(mean age 47, range 22 to 86 years) were studied by
dobutamine stress echocardiography and bicycle 
ergometry. 
Results: Mean values of body mass index, resting heart
rate and blood pressure were 28.5 kg/m2, 68 beats/min
and 129/81 mmHg, respectively. Median TSH was 51.9
mU/l, mean FT4 7.3 ± 2.9 pmol/l (mean ± SD), TT3 1.6 ±
0.6 nmol/l and total cholesterol was 5.8 ± 1.6 mmol/l.
None of the patients had symptoms of angina pectoris
during dobutamine stress echocardiography or bicycle
ergometry and no evidence of myocardial ischaemia was
demonstrated. Exercise tolerance, assessed by dividing the
maximum achieved workload by the target performance
(depending on body height, sex and age), was diminished
in 38% of patients, and significantly related to the degree
of hypothyroidism. 
Conclusion: No angina pectoris or cardiac ischaemia at
exercise or stress was found in cardiac asymptomatic
hypothyroid patients. The precise role of hypothyroidism
as a risk factor for coronary artery disease should be
further elucidated.
I N T R O D U C T I O N
Hypothyroidism and cardiac diseases have been associated
for almost a century now. In 1918, Zondek introduced the
term ‘myxoedema heart’, referring to pericardial effusion,
ventricular dilatation and hypertrophy, and interstitial
oedema with swelling of myocardial fibres.1 In 1924, a
first case of angina pectoris associated with myxoedema
was reported.2 Subsequently, several authors warned of
the danger of initiating or aggravating angina pectoris, or
even precipitating acute myocardial infarction, during
thyroid replacement therapy in patients with both
hypothyroidism and coronary artery disease.3-6 Moreover,
autopsies performed in hypothyroid patients before or
during thyroid hormone therapy demonstrated coronary
atherosclerosis and even fresh coronary occlusion.3,6-8
Independently of age, sex and associated disorders,
hypothyroidism was found to favour the development of
coronary artery atherosclerosis.7,8
Several mechanisms might be involved in this historical
association of hypothyroidism with ischaemic heart disease.
Since both abnormalities of lipid metabolism (increased
serum total cholesterol and low density lipoprotein chol-
esterol) and arterial hypertension occur with increased
frequency in hypothyroidism, those two factors are
regarded as possible causal factors.9-15 Furthermore, it has
been suggested that pathological immune reactivity in
autoimmune thyroiditis, a common cause of thyroid failure,
may be important in the above-referenced association.16
As a consequence, most physicians are still hesitant
about initiating the treatment of hypothyroid patients
with a full dosage of thyroxine, even though Singer et al.
suggest starting with a full replacement dosage of
levothyroxine in those under the age of 50 without known
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cardiac disease.17 A systematic prospective study examining
the prevalence of cardiac ischaemia before and during
treatment, however, has never been performed. Most of
the published studies on the association of hypothyroidism
with coronary artery disease were retrospective, based
only on the patient’s history without the application of
diagnostic tests, the numbers of the patients studied were
often small and, particularly in earlier studies, patients
were treated with desiccated thyroid containing differing
amounts of triiodothyroxine. 
The prevalence of coronary artery disease in untreated
hypothyroid patients needs to be known to be able to
determine the risk of angina pectoris developing during
thyroid replacement therapy. By excluding patients with a
known history of cardiac disease we were able to study only
those patients in whom the development of angina pectoris
due to coronary artery disease would be unexpected. 
We therefore conducted a prospective study in which we
determined the prevalence of cardiac ischaemia in
untreated hypothyroid patients without symptoms of
angina pectoris. 
M E T H O D S
Study population
All hypothyroid patients who presented to our hospital
between September 1999 and August 2002 were
screened for inclusion. Of these patients, only those with
longstanding primary autoimmune hypothyroidism
(TSH>4.2 mU/l and FT4<10 pmol/l) were included; the
exact duration of hypothyroidism was, therefore,
unknown. Subjects with a history of cardiac disease or
taking cardiac medication were excluded from our study
in order to evaluate the prevalence of ischaemia in
asymptomatic patients and to avoid interference of the
cardiac test results by the use of -blockers and other
cardiac medication. In total, we studied 51 consecutive
patients with untreated hypothyroidism.
At diagnosis, before thyroid hormone replacement therapy
was started, dobutamine stress echocardiography and
bicycle ergometry were performed to identify signs and/or
symptoms of myocardial ischaemia. In addition, an electro-
cardiogram was acquired, body height and weight were
measured for calculation of body mass index (BMI, kg/m2),
blood pressure was measured in a supine position and
free thyroxine (FT4), total triiodothyroxine (TT3), thyroid
stimulatory hormone (TSH), total cholesterol and choles-
terol subfractions and creatine phosphokinase (CK) were
assayed at that time.
Clinical and biochemical characteristics of the study popu-
lation were compared with those of 35 euthyroid, healthy
control subjects chosen from hospital personnel and their
relatives of comparable age who were not taking medication.
The study protocol was approved by the local medical
ethics committee, and informed consent was obtained
from each subject.
Assays
TSH plasma levels (reference range 0.4-4.2 mU/l),
serum TT3 levels (range 1.3-2.5 nmol/l) and FT4 levels
(range 10-23 pmol/l) were determined in a highly sensitive
chemiluminescent enzyme immunoassay (ACS 180, Bayer
Diagnostics, USA). Total cholesterol (range 2.5-6.5 mmol/l),
cholesterol subfractions (high-density lipoprotein (HDL)
cholesterol range 1.0-1.8 mmol/l, low-density lipoprotein
(LDL) cholesterol 1.5-4.5 mmol/l, triglycerides (TG) 0.0-
2.0 mmol/l) and creatine phosphokinase (CK 11-200 U/l)
were measured with a Hitachi 911 (Japan).
Electrocardiography
All 12-lead electrocardiograms (ECGs) were analysed by
one cardiologist and scored according to previously pub-
lished criteria.18
Dobutamine stress echocardiography
This test was performed as previously described.19
In summary, a rest ECG and a two-dimensional echo-
cardiogram were carried out and intravenous access was
secured. Dobutamine was then administered intravenously
by an infusion pump, starting at 10 g/kg/min for three
minutes, increasing by 10 g/kg/min every three minutes
up to a maximum of 40 g/kg/min. In patients not
achieving 85% of their estimated maximal heart rate
(220 beats/min minus age for men, 200 beats/min
minus age for women), atropine was administered on
top of the maximal dosage of dobutamine, starting with
0.25 mg intravenously and repeated up to a maximum of
1.0 mg. Throughout dobutamine infusion, the ECG was
continuously monitored and recorded at three-minute
intervals. Blood pressure was measured and recorded by
an automatic device every three minutes. Images were
digitised in quad screen to allow later visual analysis of
wall motion. Two experienced independent and blinded
cardiologists analysed the echocardiogram. Myocardial
ischaemia was defined as development of new or worsening
of pre-existing wall motion abnormalities in at least two
segments of the left ventricle.
Bicycle ergometry
A Lode bicycle ergometer was used. Workload was started
at 30 watts with 20-watt increments every minute. A con-
stant pedalling rate of 60 revs per minute was required
and exercise was terminated if the patient was unable to
maintain the requested cycling frequency. The ECG was
continuously monitored and blood pressure was measured
and recorded by an automatic device every two minutes.
Ischaemia was defined as development of ST depression
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of ≥0.1 mV during exercise, according to the criteria
described by Roelandt et al.20
Bicycle ergometry can also be used to assess exercise
tolerance, which could be a parameter of hypothyroid
myopathy. Therefore, at the start a target performance
was assessed for each patient, depending on body height,
age and sex. Exercise tolerance was determined by dividing
the maximum achieved workload per patient by his or her
target performance. An exercise performance of less than
80% of the target performance is considered insufficient.
Statistical analysis
Data are expressed as mean ± standard deviation (SD).
Statistical comparisons were performed by means of a
two group unpaired Students t-test. A p value <0.05 was
considered significant.
R E S U L T S
Seventy-four consecutive patients with primary 
hypothyroidism were screened for inclusion, of whom 
23 patients were excluded. Clinical and biochemical 
characteristics of the remaining 51 patients and 35 control
subjects are given in table 1. The resting blood pressure of
the experimental patients was 129/81 ± 17/12 mmHg.
The mean body mass index (BMI) was significantly higher
in hypothyroid patients compared with euthyroid controls
(28.5 ± 4.7 vs 24.1 ( 4.9 kg/m2, p=0.0004), resting heart
rate was lower (68 ± 13 vs 80 ± 9 beats/min, p=0.0001),
HDL cholesterol was lower (1.4 ± 0.4 vs 1.5 ± 0.4 mmol/l,
p<0.05), TG were higher (1.6 ± 1.0 vs 1.2 ± 0.6 mmol/l,
p<0.05) and CK was significantly higher (296 ± 746 vs 72
± 39 U/l, p=0.02). 
Twenty-three patients were excluded: 14 for cardiovascular
reasons, such as a history of cardiac disease (myocardial
infarction: n=4; angina pectoris: n=5) and cardiac medica-
tion for longstanding hypertension (n=5). Other reasons
were unwillingness to participate in the study (n=5),
hypothyroidism due to postpartum thyroiditis (n=2),
pregnancy (n=1) and myxoedema (pre)coma (n=1).
Except for age (included vs excluded patients: 47 ± 17 vs
63 ± 18 years, p<0.001) and mean TSH level (100.8 ±
136.5 vs 51.9 ± 30.4 mU/l, p<0.01), clinical and biochemical
characteristics did not differ significantly between the two
groups.
Electrocardiographic abnormalities were observed in 
24 patients: inversion of the T waves (n=4), ST-segment
depression (n=1), sinus bradycardia (heart rate <60 beats/
min, n=16), prolongation of the Q-T interval corrected for
heart rate (QTc >0.43 msec, n=4) and low P wave, QRS
and T wave amplitudes (n=5). Six of the electrocardiograms
showed two different abnormalities.
Dobutamine stress echocardiography
The echocardiogram at rest showed normal wall motion
and normal left ventricular function in all patients.
During dobutamine and later atropine administration,
none of the patients complained of angina pectoris and
none demonstrated wall motion abnormalities signifying
myocardial ischaemia. This test is not designed for the
evaluation of diastolic function.
Bicycle ergometry
As with dobutamine stress echocardiography, none of the
patients had symptoms of angina pectoris during bicycle
ergometry and no ischaemia was demonstrated. No serious
arrhythmias occurred.
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Table 1
Clinical and biochemical characteristics of the included patients and controls
INCLUDED CONTROLS P VALUE
Number 51 35
Male/female 12/39 4/31
Age (years) 47 ± 17 50 ± 12 NS
BMI (kg/m2) 28.5 ± 4.7 24.1 ± 4.9 0.0004
Heart rate (beats/min) 68 ± 13 80 ± 9 0.0001
TSH (mU/l) 100.8 ± 136.5 2.3 ± 1.1 <0.0001
FT4 (pmol/l) 7.3 ± 2.9 13.2 ± 2.1 <0.0001
TT3 (nmol/l) 1.6 ± 0.6 2.0 ± 0.6 0.002
Total cholesterol (mmol/l) 5.8 ± 1.6 5.7 ± 1.0 NS
HDL cholesterol (mmol/l) 1.4 ± 0.4 1.5 ± 0.4 <0.05
LDL cholesterol (mmol/l) 3.7 ± 1.5 3.8 ± 1.1 NS
Triglycerides (mmol/l) 1.6 ± 1.0 1.2 ± 0.6 <0.05
CK (U/l) 296 ± 746 72.3 ± 38.7 0.02
Data as mean ± SD.
Exercise tolerance was insufficient in 38% of patients
(performance of 77 ± 8% of target) and normal in 62% of
patients (performance 110 ± 13% of target). The mean
TSH levels of the patients performing insufficiently were
higher than in those with an exercise performance that
was normal according to body height, sex and age: 154.3
mU/l vs 70.2 mU/l (p<0.05, table 2). FT4 was lower in the
group with reduced exercise tolerance: 6.4 pmol/l vs 7.9
pmol/l (p<0.05). Median CK did not differ significantly
between both groups.
D I S C U S S I O N
Our study clearly showed that no cardiac ischaemia was
demonstrated in 51 consecutive patients with untreated
primary hypothyroidism without previous cardiac symptoms.
Secondly, bicycle ergometry showed that 38% of patients
performed insufficiently, indicating a significant inter-
relationship between exercise performance and degree of
hypothyroidism. This might in part be explained by
impaired cardiac performance with low cardiac output,
caused by bradycardia, a decrease in ventricular filling
and a decrease in cardiac contractility.21,22 Although cardiac
output was not measured in our patients the absence of
impaired left ventricular function makes this a very
improbable explanation. Moreover, heart rate did not differ
significantly between patients with normal or impaired
exercise performance. Another explanation might be the
existence of hypothyroid striated muscle myopathy,23,24
supported by the finding of elevated serum CK in our
patients. However, median CK levels did not differ sig-
nificantly between patients with normal or impaired
exercise performance. Finally, we observed electrocardio-
graphic abnormalities in almost half of the included
patients. It should be stressed, however, that the resting
ECG is not a diagnostic tool for demonstrating cardiac
ischaemia. Electrocardiographic abnormalities that are
frequently observed in patients with hypothyroidism are
sinus bradycardia (heart rate <60 beats/min, 31% of
patients in this study), prolongation of Q-T interval (8% in
this study) and abnormalities associated with pericardial
effusion: flattening or inversion of the T waves (8% in
this study) and low P wave, QRS and T wave amplitudes
(10% in this study).14,15 Obviously, these changes also
occur when pericardial effusion is absent, since none of
our patients had pericardial effusion.
Some possible limitations to our study should be mentioned.
First, the average age of included patients is relatively low.
An explanation for this is that we excluded patients with
cardiac history or symptoms who were relatively older.
However, the included patients did represent all ages
(range 22 to 86 years, median 46 years). Second, bicycle
ergometry may have limited sensibility and specificity for
the presence of coronary artery disease: 55 to 70% and 85
to 95%, respectively,25 with the lowest sensitivity in young
women. However, an advantage of this test is that we
were also able to assess exercise tolerance, something that
has never been done before in untreated hypothyroid
patients. Dobutamine stress echocardiography is the
most specific noninvasive test for assessing coronary
artery disease, with sensitivity and specificity of 80 and
84%, respectively.19 Third, in patients who performed
insufficiently during bicycle ergometry, evaluation of
ischaemia may be suboptimal. However, dobutamine
stress echocardiography with achievement of target heart
rate was performed in these patients and did not show
ischaemia. Finally, the included patients did not have
hypertension and dyslipidaemia. This might be caused by
the fact that nowadays hypothyroidism is often diagnosed
at an early stage due to more frequent testing of serum
TSH.
While in our study no ischaemia was demonstrated, earlier
studies have repeatedly demonstrated the association of
hypothyroidism with coronary artery disease, even in
previously cardiac asymptomatic patients, and of hormone
replacement therapy with angina pectoris.1-9,15,26-27
However, a retrospectively reviewed Mayo Clinic series of
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Table 2
TSH and FT4 in patients with insufficient and normal exercise performance
INSUFFICIENT NORMAL P VALUE
Number 19 31
Male/female 8/11 4/27
Ever smokers 8 8
TSH (mU/l) 154.3 ± 202.6 70.2 ± 58.8 0.047
FT4 (pmol/l) 6.4 ± 3.2 7.9 ± 2.6 0.045
TT3 (nmol/l) 1.3 ± 0.7 1.6 ± 0.5 NS
Systolic BP (mmHg) 124 ± 15 132 ± 17 0.046
Diastolic BP (mmHg) 80 ± 11 80 ± 12 NS
Heart rate (beats/min) 69 ± 11 67 ± 14 NS
Data as mean ± SD.
over 1500 patients with myxoedema shows that angina
pectoris and myocardial infarction are rather infrequent
among hypothyroid patients: just 4% had angina pectoris
before thyroid replacement therapy was started and 2% of
cardiac asymptomatic patients developed angina pectoris
after treatment had begun. Thirty-eight percent of patients
with angina pectoris before initiating thyroid hormone
replacement were even reported to improve.6 This may be
explained by the fact that thyroid hormone replacement
improves myocardial oxygen consumption.28 Most of the
above-mentioned studies on hypothyroidism and coronary
artery disease, however, can be criticised for being either
retrospective or uncontrolled, for small sample sizes or
for using desiccated thyroid containing differing amounts
of levothyroxine and triiodothyroxine. Patients are now
treated by L-T4 only: as this first has to be converted by
the liver into T3 by type I deiodinase, the heart is probably
protected against high elevations of plasma T3 levels. A
systematic consecutive study on this association has
never been reported. 
Interestingly, few studies have been published in which
dobutamine stress echocardiography is performed in
asymptomatic patients with other known risk factors for
coronary artery disease and no studies in hypothyroid
patients have been performed before. We found one
study in which dobutamine stress echocardiography was
performed in asymptomatic diabetic patients having at
least three added risk factors but without rest ECG
abnormalities. The authors concluded that asymptomatic
coronary artery disease is common in diabetes associated
with other risk factors. Moreover, dobutamine stress
echocardiography appeared useful in its detection with a
predictive positive value of 69%.29 We did not find any
studies of cardiac asymptomatic subjects with hyper-
lipidaemia and no studies of dobutamine stress echo-
cardiography in cardiac asymptomatic subjects without
risk factors for coronary artery disease. 
Further research should include a prospective study in
which development of angina pectoris during thyroid
replacement therapy is monitored, as this could have
important implications for future therapy. It is imaginable
that patients who are treated initially with a higher dose
of thyroxine will be euthyroid, and might feel better, much
sooner than patients treated according to the present
principle of starting low and increasing slow. Moreover,
elevated arterial blood pressure and high serum cholesterol,
both predisposing factors for coronary artery disease,
might decrease sooner.
C O N C L U S I O N
In conclusion, our data show that none of the cardiac
asymptomatic patients with untreated hypothyroidism
showed angina pectoris during stress testing and that no
signs of ischaemia were found in these patients. The 
precise role of hypothyroidism as a risk factor for coro-
nary artery disease should further be elucidated.
A C K N O W L E D G M E N T S
We are grateful to I. Jongste for excellent nursing services
at the clinics of our outpatients department, 
R.T. van Domburg (epidemiologist, Erasmus Medical
Centre, Rotterdam) for providing statistical analysis of
our data, F.J. ten Cate (cardiologist, Erasmus Medical
Centre, Rotterdam), for analysing the dobutamine stress
echocardiograms and Professor J.P. Tijssen (clinical epi-
demiologist, Amsterdam Medical Centre) for critical
appraisal of the manuscript.
R E F E R E N C E S
1. Zondek H. Das myxödemherz. München Med Wehnsch 1918;2:1180-2. 
2. Laubry C, Mussio-Fournier, Walser J. Syndrome angineux et insuffisance
thyroidienne. Bull Mém Soc Méd Hôp Paris 1924;48:1924.
3. Smyth CJ. Angina pectoris and myocardial infarction as complications of
myxedema. With especial reference to the danger of treatment with thyroid
preparations. Am Heart J 1938;15:652-60.
4. Becker C. Hypothyroidism and atherosclerotic heart disease: pathogenesis,
medical management, and the role of coronary artery bypass surgery.
Endocr Rev 1985;6:432-440.
5. Lindsay RS, Toft AD. Hypothyroidism. Lancet 1997;349:413-7.
6. Keating FR, Parkin TW, Selby JB, Dickinson LS. Treatment of heart disease
associated with myxedema. Prog Cardiovasc Dis 1961;3:364-81.
7. Vanhaelst L, Neve P, Chailly P, Bastenie PA. Coronary-artery disease in
hypothyroidism. Observations in clinical myxedema. Lancet 1967;2:800-2.
8. Steinberg AD. Myxedema and coronary artery disease: a comparative
autopsy study. Ann Intern Med 1968;68:338-44.
9. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid
disease prevalence study. Arch Intern Med 2000;160:526-34.
10. Diekman T, Demacker PNM, Kastelein JJP, Stalenhoef AFH, Wiersinga WM.
Increased oxidizability of low-density lipoproteins in hypothyroidism. 
J Clin Endocrinol Metab 1998;83:1752-5.
11. Saito I, Saruta T. Hypertension in thyroid disorders. Endocrinol Metab
Clin North Am 1994;23:379-86.
12. Tielens E, Visser TJ, Henneman G, Berghout A. Cardiovascular effects of
hypothyroidism. Ned Tijdschr Geneeskd 2000;144:703-6.
13. Fommei E, Iervasi G. The role of thyroid hormone in blood pressure
homeostasis: evidence from short-term hypothyroidism in humans. 
J Clin Endocrinol Metab 2002;87:1996-2000.
14. Williams GH, Lilly LS, Seely EW. The heart in endocrine and nutritional
disorders. Braunwald Heart Disease. 5th edition. 1997. p. 1894-5.
15. Colluci WS, Braunwald E. Cardiovascular manifestations of systemic
diseases. Harrison’s Principles of Internal Medicine. 14th edition. 1998.
p. 1342-4. 
Roos, et al. Evaluation of cardiac ischaemia.
M A R C H  2 0 0 5 ,  V O L .  6 3 ,  N O .  3
101
16. Mathews JD, Whittingham S, Mackay IR. Autoimmune mechanisms in
human vascular disease. Lancet 1974;7894:1423-7.
17. Singer EA, Cooper DS, Levy EG, et al. Treatment guidelines for patients
with hyperthyoidism and hypothyroidism. JAMA 1995;273:808-12.
18. Braunwald E (ed). Electrocardiography and vectorcardiography.
Braunwald Heart Disease. 4th edition. 1992. p. 116-52.
19. Geleijnse ML, Fioretti PM, Roelandt JRTC. Methodology, feasibility, safety
and diagnostic accuracy of dobutamine stress echocardiography. J Am
Coll Cardiol 1997;30:595-606.
20. Roelandt JRTC, Lie KI, Wellens HJJ, van der Werf F. Electrocardiography.
Leerboek cardiologie. 1995. p. 111-6.
21. Klein I, Ojama K. Thyroid hormone and the cardiovascular system. N Engl
J Med 2001;344:501-9.
22. Crowley WF, Ridgway EC, Bough EW, et al. Noninvasive evaluation of
cardiac function in hypothyroidism. N Engl J Med 1997;296:1-6.
23. Khaleeli AA, Griffith DG, Edwards RH. The clinical presentation of
hypothyroid myopathy and its relationship to abnormalities in structure
and function of skeletal muscle. Clin Endocrinol (Oxf) 1983;19(3):365-76.
24. Kaminski HJ, Ruff RL. Endocrine myopathies. Myology. 2nd edition. 1994.
p. 1741-2.
25. Deckers JW, Rensing BJ, Tijssen JGP, Vinke RVH, Azar AJ, Simoons ML.
A comparison of methods of analyzing exercise tests for diagnosis of
coronary artery disease. Br Heart J 1989;62:438-44.
26. Levine HD. Comprise therapy in the patients with angina pectoris and
hypothyroidism, a clinical assessment. Am J Med 1980;69:411-7.
27. Wartofsky L. Diseases of the thyroid. Harrison’s Principles of Internal
Medicine. 14th edition. 1998. p. 2021-3.
28. Bengel FM, Nekolla SG, Ibrahim T, Weniger C, Ziegler SI, Schwaiger M.
Effect of thyroid hormones on cardiac function geometry, and oxidative
metabolism assessed noninvasively by positron emission tomography
and magnetic resonance imaging. J Clin Endocrinol Metab
2000;85:1822-7.
29. Penfonis A, Zimmermann C, Boumal D, Sabbah A, et al. Use of dobutamine
stress echocardiography in detecting silent myocardial ischaemia in
asymptomatic diabetic patients: a comparison with thallium scintigraphy
and exercise testing. Diabet Med 2001;18:900-5.
M A R C H  2 0 0 5 ,  V O L .  6 3 ,  N O .  3
Roos, et al. Evaluation of cardiac ischaemia.
102
